Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04731376 · ClinicalTrials.gov registry record · Phase 1
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
A Phase 1 study of Hypogonadism and Malignant Urinary System Neoplasm, sponsored by Emory University.
- Active
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT04731376 is a Phase 1 study of Hypogonadism and Malignant Urinary System Neoplasm that is active but no longer recruiting, run by Emory University. The registered enrollment target is 56 participants, below the 118-participant average among 21 other Hypogonadism trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04731376, a Phase 1 study of Hypogonadism and Malignant Urinary System Neoplasm, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial investigates the safety of testosterone replacement therapy around the time of major urologic surgery (perioperative) in order to improve quality of life and post-operative outcomes such as decreased length of hospital stay, complications, and mortality in patients with low testosterone levels. Studies have demonstrated that patients undergoing testosterone replacement therapy have increased lean body mass, decreased fat mass and have improved physical function. Testosterone replacement therapy can also stimulate bone formation and may decrease the risk of fracture. Information from this trial may be used to support the incorporation of testosterone level testing and testosterone replacement into the perioperative treatment decision-making process.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Best Practice
- DRUG Testosterone Cypionate
- PROCEDURE Quality-of-Life Assessment
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-01-25 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04731376
The ClinicalTrials.gov registry entry for NCT04731376 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 118-participant average among 21 other Hypogonadism trials with a reported enrollment target (53% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Hypogonadism appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT04731376 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT04731376 about?
NCT04731376 is a clinical study titled "Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone". This phase I trial investigates the safety of testosterone replacement therapy around the time of major urologic surgery (perioperative) in order to improve quality of life and post-operative outcomes such as decreased length of hospital stay, complications, and mortality in patients with low testos...
What is the current status of trial NCT04731376?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2021-01-25. Estimated completion is 2026-12-31.
What conditions does trial NCT04731376 study?
This clinical trial studies the following conditions: Hypogonadism, Malignant Urinary System Neoplasm, Urinary System Disorder, Urinary System Neoplasm.
What interventions are being tested in trial NCT04731376?
The interventions under investigation include: Questionnaire Administration (OTHER), Best Practice (OTHER), Testosterone Cypionate (DRUG), Quality-of-Life Assessment (PROCEDURE).
Who is sponsoring clinical trial NCT04731376?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04731376 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure
COMPLETED · Phase 1
-
ORAL T-6: Oral Androgens in Man-6
COMPLETED · Phase 1
-
Observation of Environment and Reproductive-Endocrine Effects
RECRUITING
-
Adaptions and Resiliency to Multi-Stressor OpeRations
RECRUITING · Phase 4
-
Inherited Reproductive Disorders
RECRUITING
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.